White Papers / Tech Papers

Soft Midst Inhalers: Lung Deposition Benefits for Respiratory Conditions

Soft Mist Inhalers market expected to grow at a CAGR of 6.8% from 2023 to 2031 and reach more than £4.4 Bn by the end of 2031.

Company Logo

Released By Upperton


Biopharma companies are under continued pressure to respond to the global increase in acute respiratory conditions, with the global market for inhalation drug delivery devices expected to reach $20.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.4%. With direct delivery to target sites, rapid onset of action and a reduced risk of systemic side effects compared to oral therapies, the inhalation market is growing at a phenomenal rate. 

Soft Mist Inhalers market expected to grow at a CAGR of 6.8% from 2023 to 2031 and reach more than £4.4 Bn by the end of 2031.

Download the eBook below to learn more.

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters